Patent · US9650680B2 · B2 · US
MicroRNAs and uses thereof
- (11) Publication number
- US9650680B2
- (21) Application number
- 14/999,879
- (22) Filing date
- 2016-07-13
- (30) Priority date
- 2004-05-14
- (43) Publication date
- 2017-05-16
- (45) Date of grant
- 2017-05-16
- (51) IPC
- C12N 15/11; C12Q 1/68; A61K 38/00; C07H 21/04; C12N 15/113
- (52) CPC
- C12N Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media: 15/113, 15/111, 2310/14, 2310/141, 2310/531, 2320/10, 2320/11, 2320/30, 2330/10
- A61K Preparations for medical, dental or toiletry purposes: 38/00
- A61P Specific therapeutic activity of chemical compounds or medicinal preparations: 35/00
- C12Q Measuring or testing processes involving enzymes, nucleic acids or microorganisms; compositions or test papers therefor; processes of preparing such compositions; condition-responsive control in microbiological or enzymological processes: 1/6809, 1/6876, 1/6886, 2600/106, 2600/136, 2600/158, 2600/16, 2600/178
- Y02A Technologies for adaptation to climate change: 90/10
- (73) Assignee
- Rosetta Genomics Ltd
- (72) Inventors
- Itzhak Bentwich; Amir Avniel; Yael Karov; Ranit Aharonov
- (54) Title
- MicroRNAs and uses thereof
- (57) Abstract
Described herein are novel polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.
- Full text
- View on Google Patents
Claims (3)
- A nucleic acid selected from the group consisting of: (a) a nucleic acid of 18-24 nucleotides comprising at least 18 contiguous nucleotides identical to SEQ ID NO: 18611; (b) a DNA encoding the nucleic acid of (a), wherein the DNA is identical in length to (a); (c) the complement of one of the nucleic acids of (a) and (b), wherein the complement is identical in length to the one of the nucleic acids of (a) and (b); wherein the nucleic acid comprises a non-naturally occurring nucleotide.
- A probe comprising a heterologous sequence, wherein the heterologous sequence consists a nucleic acid sequence selected from the group consisting of: (a) a sequence of 18-24 nucleotides comprising at least 18 contiguous nucleotides identical to SEQ ID NO: 18611; (b) a DNA encoding the sequence of (a), wherein the DNA is identical in length to (a); (c) the complement of one of the sequences of (a) and (b), wherein the complement is identical in length to the one of the sequences of (a) and (b), wherein the probe comprises at least one of a non-naturally occurring nucleotide and a label.
- A vector comprising a heterologous sequence, wherein the heterologous sequence consists of a nucleic acid sequence selected from the group consisting of (a) a sequence of 18-24 nucleotides comprising at least 18 contiguous nucleotides identical to SEQ ID NO: 18611; (b) a DNA encoding the sequence of (a), wherein the DNA is identical in length to (a); (c) the complement of one of the sequences of (a) and (b), wherein the complement is identical in length to the one of the sequences of (a) and (b).
Description
The invention relates in general to microRNA molecules as well as various nucleic acid molecules relating thereto or derived therefrom.
MicroRNAs (miRNAs) are short RNA oligonucleotides of approximately 22 nucleotides that are involved in gene regulation. MicroRNAs regulate gene expression by targeting mRNAs for cleavage or translational repression. Although miRNAs are present in a wide range of species including C. elegans, Drosophilla and humans, they have only recently been identified. More importantly, the role of miRNAs in the development and progression of disease has only recently become appreciated.
As a result of their small size, miRNAs have been difficult to identify using standard methodologies. A limited number of miRNAs have been identified by extracting large quantities of RNA. MiRNAs have also been identified that contribute to the presentation of visibly discernable phenotypes. Expression array data shows that miRNAs are expressed in different developmental stages or in different tissues. The restriction of miRNAs to certain tissues or at limited developmental stages indicates that the miRNAs identified to date are likely only a small fraction of the total miRNAs.
Computational approaches have recently been developed to identify the remainder of miRNAs in the genome. Tools such as MiRscan and MiRseeker have identified miRNAs that were later experimentally confirmed. Based on these computational tools, it has been estimated that the human genome contains 200-255 miRNA genes.
Citations (9)
- WO2004016317A1
- US7655785B1
- US7820809B2
- US7250289B2
- US7407784B2
- US20050075492A1
- US20120094374A1
- US20080269072A1
- US20080125583A1
Record as JSON
{
"publication_number": "US9650680B2",
"country": "US",
"kind": "B2",
"title": "MicroRNAs and uses thereof",
"abstract": "Described herein are novel polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.",
"claims": [
"1. A nucleic acid selected from the group consisting of: (a) a nucleic acid of 18-24 nucleotides comprising at least 18 contiguous nucleotides identical to SEQ ID NO: 18611; (b) a DNA encoding the nucleic acid of (a), wherein the DNA is identical in length to (a); (c) the complement of one of the nucleic acids of (a) and (b), wherein the complement is identical in length to the one of the nucleic acids of (a) and (b); wherein the nucleic acid comprises a non-naturally occurring nucleotide.",
"2. A probe comprising a heterologous sequence, wherein the heterologous sequence consists a nucleic acid sequence selected from the group consisting of: (a) a sequence of 18-24 nucleotides comprising at least 18 contiguous nucleotides identical to SEQ ID NO: 18611; (b) a DNA encoding the sequence of (a), wherein the DNA is identical in length to (a); (c) the complement of one of the sequences of (a) and (b), wherein the complement is identical in length to the one of the sequences of (a) and (b), wherein the probe comprises at least one of a non-naturally occurring nucleotide and a label.",
"3. A vector comprising a heterologous sequence, wherein the heterologous sequence consists of a nucleic acid sequence selected from the group consisting of (a) a sequence of 18-24 nucleotides comprising at least 18 contiguous nucleotides identical to SEQ ID NO: 18611; (b) a DNA encoding the sequence of (a), wherein the DNA is identical in length to (a); (c) the complement of one of the sequences of (a) and (b), wherein the complement is identical in length to the one of the sequences of (a) and (b)."
],
"description_excerpt": "The invention relates in general to microRNA molecules as well as various nucleic acid molecules relating thereto or derived therefrom.\n\nMicroRNAs (miRNAs) are short RNA oligonucleotides of approximately 22 nucleotides that are involved in gene regulation. MicroRNAs regulate gene expression by targeting mRNAs for cleavage or translational repression. Although miRNAs are present in a wide range of species including C. elegans, Drosophilla and humans, they have only recently been identified. More importantly, the role of miRNAs in the development and progression of disease has only recently become appreciated.\n\nAs a result of their small size, miRNAs have been difficult to identify using standard methodologies. A limited number of miRNAs have been identified by extracting large quantities of RNA. MiRNAs have also been identified that contribute to the presentation of visibly discernable phenotypes. Expression array data shows that miRNAs are expressed in different developmental stages or in different tissues. The restriction of miRNAs to certain tissues or at limited developmental stages indicates that the miRNAs identified to date are likely only a small fraction of the total miRNAs.\n\nComputational approaches have recently been developed to identify the remainder of miRNAs in the genome. Tools such as MiRscan and MiRseeker have identified miRNAs that were later experimentally confirmed. Based on these computational tools, it has been estimated that the human genome contains 200-255 miRNA genes.",
"cpc": [
"C12N 15/113",
"A61K 38/00",
"A61P 35/00",
"C12N 15/111",
"C12N 2310/14",
"C12N 2310/141",
"C12N 2310/531",
"C12N 2320/10",
"C12N 2320/11",
"C12N 2320/30",
"C12N 2330/10",
"C12Q 1/6809",
"C12Q 1/6876",
"C12Q 1/6886",
"C12Q 2600/106",
"C12Q 2600/136",
"C12Q 2600/158",
"C12Q 2600/16",
"C12Q 2600/178",
"Y02A 90/10"
],
"ipc": [
"C12N 15/11",
"C12Q 1/68",
"A61K 38/00",
"C07H 21/04",
"C12N 15/113"
],
"assignees": [
"Rosetta Genomics Ltd"
],
"inventors": [
"Itzhak Bentwich",
"Amir Avniel",
"Yael Karov",
"Ranit Aharonov"
],
"filing_date": "2016-07-13",
"publication_date": "2017-05-16",
"grant_date": "2017-05-16",
"priority_date": "2004-05-14",
"application_number": "US-201614999879-A",
"family_id": "35394738",
"cited_by_count": 3,
"citations": [
"WO2004016317A1",
"US7655785B1",
"US7820809B2",
"US7250289B2",
"US7407784B2",
"US20050075492A1",
"US20120094374A1",
"US20080269072A1",
"US20080125583A1"
]
}
Record 4,118 of 8,000 in Patents full text (MLC-0201). Request the full dataset.